Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
PRECISION BIOSCIENCES INC (DTIL) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/04/2023 8-K Quarterly results
Docs: "Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update - FDA Advice Provides Clarity on Future Development for Lead CAR T Program Candidate Azer-Cel; CAR T Partnering Discussions Ongoing - Presented Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy and Chronic Hepatitis B - Company plans to host In Vivo Gene Editing R&D Day on September 12, 2023 - Cash Balance Provides Expected Runway Through Q1 2025"
05/09/2023 8-K Quarterly results
Docs: "Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update - Program Updates Planned for Azer-cel and PBCAR19B in May 2023 - Presented data on PBGENE-HBV program at Global Hepatitis Summit 2023; PBGENE-DMD program data update upcoming at ASGCT Conference - In Vivo Gene Editing R&D Day Planned for Mid-2023 - Cash Balance Provides Expected Runway through Q1 2025"
03/09/2023 8-K Quarterly results
Docs: "Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update - Advanced ARCUS Gene Editing Development for Clinical and Research Programs; In Vivo Gene Editing R&D Day Planned for Mid-2023 - Progressed Azer-cel and PBCAR19B Allogenic CAR T Clinical Studies; Program Updates Planned for Azer-cel and PBCAR19B - Advanced Wholly Owned, Preclinical PBGENE-HBV and Partnered DMD, Sickle Cell Disease, and OTC Programs; New Data Expected to be Presented/Published in 2023 - Cash Balance Provides Expected 2-Year Runway through Q1 2025"
11/08/2022 8-K Quarterly results
Docs: "Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update - Allogeneic CAR T Program Updates Planned for Late Q4 2022 or Early Q1 2023 - Abstract Showcasing Functional Attributes of Azer-cel Accepted for Presentation at the 64th American Society of Hematology Annual Meeting - Preclinical Research on In Vivo Gene Editing Programs Presented at the European Society of Gene & Cell Therapy 29th Congress - Strong Cash Position Provides More than Two Years of Expected Runway"
08/08/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
03/15/2022 8-K Quarterly results
Docs: "Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update -"
11/10/2021 8-K Quarterly results
Docs: "Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Business Update -"
03/18/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "Precision BioSciences Reports Third Quarter 2020 Financial Results and Provides Business Update Expanded allogeneic CAR T development collaboration with Servier to include four new programs targeting hematological and solid tumors"
08/13/2020 8-K Quarterly results
05/15/2020 8-K Quarterly results
Docs: "Precision BioSciences Reports First Quarter 2020 Financial Results and Provides Business Update Dosed First Patient in Phase 1/2a Clinical Study of PBCAR20A in Relapsed/Refractory NHL, CLL, and SLL"
03/10/2020 8-K Quarterly results
Docs: "Precision BioSciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update -Presented initial clinical data for lead allogeneic CAR T program PBCAR0191 for the treatment of NHL and B-ALL-"
11/12/2019 8-K Quarterly results
08/14/2019 8-K Quarterly results
04/29/2019 8-K Quarterly results
Docs: "Precision BioSciences Reports First Quarter 2019 Financial Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy